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Major depressive disorder (MDD) contributes to a significant worldwide disease burden, 
expected to be second only to heart disease by 2050. However, accurate diagnosis 
has been a historical weakness in clinical psychiatry. As a result, there is a demand for 
diagnostic modalities with greater objectivity that could improve on current psychiatric 
practice that relies mainly on self-reporting of symptoms and clinical interviews. Over 
the past two decades, literature on a growing number of putative biomarkers for MDD 
increasingly suggests that MDD patients have significantly different biological profiles 
compared to healthy controls. However, difficulty in elucidating their exact relationships 
within depression pathology renders individual markers inconsistent diagnostic tools. 
Consequently, further biomarker research could potentially improve our understanding 
of MDD pathophysiology as well as aid in interpreting response to treatment, narrow dif-
ferential diagnoses, and help refine current MDD criteria. Representative of this, multiplex 
assays using multiple sources of biomarkers are reported to be more accurate options 
in comparison to individual markers that exhibit lower specificity and sensitivity, and are 
more prone to confounding factors. In the future, more sophisticated multiplex assays 
may hold promise for use in screening and diagnosing depression and determining 
clinical severity as an advance over relying solely on current subjective diagnostic criteria. 
A pervasive limitation in existing research is heterogeneity inherent in MDD studies, which 
impacts the validity of biomarker data. Additionally, small sample sizes of most studies 
limit statistical power. Yet, as the RDoC project evolves to decrease these limitations, 
and stronger studies with more generalizable data are developed, significant advances in 
the next decade are expected to yield important information in the development of MDD 
biomarkers for use in clinical settings.
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iNTRODUCTiON
Major depressive disorder (MDD) is a highly prevalent illness in the United States that causes broad 
functional impairments (1) with significant public health costs (2, 3) and evidence of increasing 
rates over the past few decades (4). Together, this indicates that there is significant need to develop 
an objective characterization of the disorder for screening and diagnostics. The diagnosis of MDD 
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currently relies on the clinical judgment of individual clinicians 
with high levels of subjectivity and potential variability. Following 
the publication of the fifth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM 5), concerns have 
been expressed with regards to the revised definition of MDD 
(5). Although based on opinion, the response to the changes 
of diagnostic criteria has highlighted how differing beliefs exist 
with regards to the MDD diagnosis, the subjectivity of diagnos-
ing depressed patients, and the perception of a decrease in the 
reliability of MDD criteria under DSM 5 guidelines (5). Concerns 
about the validity of psychiatric diagnosis for depressive disor-
ders is disconcerting and further emphasize the demand for more 
objective diagnostic modalities to assess MDD, such as blood-
based and cerebrospinal fluid (CSF) biomarkers. Although there 
has been a significant amount of research in the development of 
fluid biomarkers for use in establishing MDD diagnosis (6–10), a 
consensus on which biomarkers are sensitive and specific enough 
to be used in a clinical setting has yet to be reached (11). In fact, 
studies of putative monoaminergic biomarkers such as peripheral 
and CSF levels of serotonin, dopamine, and noradrenaline often 
report conflicting results (12). Fortunately, there has also been an 
increased interest in other potential approaches by which MDD 
biomarkers may be discovered (13, 14). The objective of this 
article is to provide a broad overview of several types of biomark-
ers for MDD currently being investigated and to describe recent 
progress in identifying biomarkers that may potentially aid in the 
standardization of MDD diagnosis. Due to the sizeable literature 
investigating candidate MDD biomarkers and the limited space 
afforded to the authors, this overview will only focus on a select 
number of tissue-based biomarkers and recent multiplex studies 
published before December 1, 2015, while excluding current 
literature from the burgeoning neuroimaging biomarker data of 
structural imaging that has been previously reviewed (15–17).
BiOMARKeR CANDiDATeS
Hypothalamic–Pituitary–Adrenal Axis (DST, 
DeX/CRH, Cortisol Response, Hypocretin)
HPA-axis hyperactivity has been associated with a spectrum of 
neuropsychiatric disorders due to its deleterious effects on the 
nervous system including dendritic process atrophy, decreased 
neurogenesis and neuroplasticity, and neuronal losses (18, 19); 
consequently, a wide range of biomarkers may be disrupted by 
HPA-axis dysfunction, such as disturbed adrenocorticotropic 
hormone (ACTH) regulation, dysfunctional corticosteroid 
receptor signaling, and glucocorticoid (GR) excess (18).
Furthermore, mutations in genetic regions involved in abnor-
mal HPA-axis function (such as the FKBP5 allele) have also been 
associated with an increased risk for depression, and are similarly 
associated with abnormal plasma cortisol and ACTH concentra-
tions (20–23).
However, beyond genetic factors, epidemiologic and clinical 
studies have determined that disturbances in HPA axis function 
have been consistently associated with biological changes in 
depression (24, 25). For example, one facet of depression history 
that is associated with HPA axis changes is early life stress. Early 
life stress (e.g., maltreatment or abuse) was found to result in HPA 
axis dysfunction during childhood and adolescence and contrib-
uted to an increased risk of developing MDD later in life (26).
Moreover, diminished cortisol suppression following dexa-
methasone (DEX) administration was observed in MDD patients 
with metabolic abnormalities of prefrontal and hippocampal 
regions, areas often related to MDD pathology (27). Other studies 
found that antidepressant treatment often resulted in decreased 
cortisol levels and a return to normal HPA axis function (28, 29).
Originally, as corticotrophin-releasing hormone (CRH) has 
been reported to be associated with increased depressive symp-
toms such as anhedonia and reduced appetite (30), a combined 
DEX/CRH test was thought to be capable of increasing diagnostic 
power over the Dexamethasone Suppression Test (DST) (12, 
31). However, abnormal DEX/CRH results also occur in other 
psychiatric disorders resulting in lack of specificity as a diagnostic 
biomarker for major depression (12). Measuring cortisol levels 
is a more direct and accurate method of assessing HPA axis 
activity in depressed patients (32). Additionally, more recent 
studies focusing on cortisol measurements have demonstrated a 
link between cortisol levels and depression severity or depressive 
subtypes.
A recent meta-analysis (33) reports a significant association 
between HPA-axis hyperactivity as measured by elevated cortisol 
levels and the presence of melancholic or psychotic depression 
while lower cortisol levels were characteristic of depression with 
atypical features. For example, a longitudinal study of adolescents 
with depressive symptoms found that male adolescents with 
high morning salivary cortisol levels and increased depressive 
symptoms were more susceptible to the development of MDD 
demonstrating a sex-linked differentiation (34).
Another study also reported that persistent increases in 
cortisol awakening response (CAR) in adolescents more strongly 
correlated with higher levels of depressive symptoms than with 
anxiety symptoms (35). Lastly, a large cohort study confirmed 
increased CAR and dynamic cortisol secretion in depressed 
patients compared to controls in both current MDD and remit-
ted MDD subjects, indicating that both measurements reflect 
an inherent risk in the development of depression (29). These 
studies suggest the use of morning salivary cortisol as a trait-like 
biomarker for developing preventative measures for high-risk 
populations, especially in asymptomatic individuals with possible 
genetic risks (36). However, a recent study revealed that increased 
CAR in healthy female adolescents significantly correlated with 
higher magnitudes of Profile of Mood States (POMS) subscale 
scores for “Tension-Anxiety,” “Depression-Dejection,” “Fatigue,” 
and “Confusion” (37) suggesting that morning salivary cortisol 
levels may also be descriptive of mood states and episodic depres-
sive symptoms rather than characteristic of a purely trait marker 
for MDD. Such findings suggest variability in the use of salivary 
cortisol as a depression biomarker. However, it is important to 
consider how these contrasting conclusions may be affected by 
methodological heterogeneity and differences in subject popula-
tions among these studies.
Another possible biomarker source includes hypocretin, a 
neuropeptide that plays a role in sleep and arousal. Recently, 
it has been suggested that decreased numbers and size of 
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hypocretin-containing neurons may be associated with the 
development of depressive symptoms including eating/drink-
ing behaviors and disrupted sleep (38, 39). One study found 
that hypocretin levels in the CSF of MDD-diagnosed patients 
with high suicidal ideation were significantly lower than those 
of patients with dysthymia and adjustment disorder (40). 
Additionally, hypocretin levels correlated significantly with CSF 
levels of other peptides that affect sleep and appetite including 
delta sleep-inducing-peptide-like immunoreactivity (DSIP-IL), 
CRF, and somatostatin. Not only are these results indicative of 
the diagnostic utility of measuring hypocretin concentrations but 
also these peptides may also be useful in discriminating affec-
tive disorders by associating differing biological characteristics 
with signs and symptoms of depression. However, one study 
reported results that counter the more common conception of 
lower hypocretin levels in depression (41). Bearing in mind that 
the relatively few studies and the dynamic character of HPA axis 
components in general concerning hypocretin-based biomarkers 
for depression, future studies would be instrumental in further 
elucidating hypocretin effects in depressed patients.
Thyroid Function and Thyroid 
Autoimmunity
A number of studies have related thyroid dysfunction with 
depressive symptoms and depressive disorders (42–50). However, 
a direct correlation is indeterminate as evidenced by a number 
of conflicting studies (51–56). More recent studies have shown 
a relationship between levels of antithyroid antibodies with 
depression (57–59) and poorer “psychosocial well-being” (60). 
However, there also exists literature demonstrating equivocal 
data concerning this association (61). In fact, one group found 
that thyroid function and thyroid autoantibody levels were not 
associated with depression severity despite an association with 
the presence of depressive symptoms (58). Supporting these 
results, a general population study showed no significant dif-
ference in depressive symptoms between euthyroid individuals 
and those characterized to have subclinical hypothyroidism (62). 
Conversely, another general population study found an increase 
in prevalence of lifetime depression diagnosis in subjects positive 
for thyroid peroxidase antibodies, suggesting its use as a trait 
marker for depression despite finding no association between 
depression disorder diagnosis and TSH or free T4 levels (63). 
Interestingly, one study (64) found T3 and T4 levels derived from 
hair were significantly lower in patients concurrently having a 
depressed episode (P <  0.001), which may indicate the use of 
thyroid hormones as a state-like biomarker. In this sense, future 
studies should focus on readily accessible markers of thyroid 
function that have some state-like diagnostic utility in major 
depression diagnosis as studies researching their use as trait-like 
markers have demonstrated mostly equivocal results.
Cytokines and inflammatory Markers
There also exists an abundance of evidence that elevated proin-
flammatory cytokine concentrations and an increased immune 
response are associated with depression diagnosis, symp-
tomatology, and severity (65–69). Reflective of this significant 
proinflammatory response in depressive disorders, a recent 
proteomic study found elevated levels of acute phase reactants 
(e.g., ferritin, serotransferrin, Haptoglobin-related protein, 
ceruloplasmin) and proinflammatory markers (e.g., IL-16, 
MIF, Tenascin-C, and EN-RAGE) in drug-naive MDD patients, 
indicating a disorder-related increase in immune processes (70). 
These findings are supported by neuroimaging and animal stud-
ies, which have demonstrated that alterations in neuroplasticity 
promote manifestations of depressive phenotypes as a result of 
cytokine-induced neural apoptosis and metabolic dysregulation 
(71). Further, inflammatory cytokines have been described to 
alter basal ganglia processes leading to common depressive 
phenotypical characteristics including anhedonia, fatigue, and 
psychomotor retardation (72–75). A recent review also reported 
increased neopterin levels in a number of studies of depressed 
patients, specifically in melancholic subtypes of depression (76). 
Additionally, inflammatory markers IL-6 and soluble intercellu-
lar adhesion molecule (sICAM) have been associated with sleep 
disturbances in depressed patients (77). IL-8 and TNF-α have also 
been reported to remain elevated in certain subsets of depressed 
patients after antidepressant therapy, indicating possible trait 
characteristics (78).
C-reactive protein (CRP) and interleukin (IL)-6, specifically, 
have been found to exhibit trait characteristics (i.e., gender 
effects, impact of early life adverse events) as an inflammatory 
biomarker for depressive pathology (79–82). In their meta-
analysis, Valkanova and colleagues (83) found that these two 
putative analytes had a small but significant association with the 
development of depressive symptoms, indicating the presence 
of raised inflammatory markers preceding the development of 
MDD. However, the authors cautioned that their results might 
have limited significance due to heterogeneity (i.e., of depression, 
methodologies, populations, etc.) across studies.
For instance, one study (84) found both higher and lower 
levels of different inflammatory markers in major depressed 
patients depending on the presence or absence of melancholic 
features, indicating that that the overall characteristics of depres-
sive symptoms were more associated with the composition of 
inflammatory profiles and less so on concentrations of individual 
markers. Moreover, a study of an elderly population found that 
when controlling for age-related chronic diseases, CRP was not 
a statistically significant marker associated with the presence 
of MDD or sub-threshold depression (85). Lastly, one group 
reported significantly lower levels of IL-6 in subjects with high 
self-reported depressive symptoms while showing no significant 
differences of IL-8, IL-10, and TNF-α levels when compared to 
controls (86). As a whole, these studies demonstrate the complexi-
ties of relying on individual inflammatory marker concentrations 
to characterize generalized depression.
Yet, there is reasonable evidence that suggests inflammatory 
responses are more prominent in certain subsets of MDD than 
others. A study evaluating biomarker associations with depres-
sive subtypes found that increased inflammatory markers (i.e., 
CRP, IL-6, TNF-α) were significantly associated with atypical 
depression as compared to typical or melancholic depression (87). 
Consistent with these results, a more recent study (88) reported 
that elevated IL-6 levels were consistently higher in patients with 
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atypical depression. Similarly, a recent study has detected consist-
ently increased CRP levels in depressed patients with comorbid 
diabetes mellitus (89). Moreover, these studies reinforce clinical 
evidence that both inflammatory diseases and depression are 
often associated with comorbid illnesses like metabolic disorders 
(87, 90), especially in more elderly subjects (91–93). It is possible 
that in many cases, the predisposition to depression in patients 
with elevated inflammatory biomarker concentrations is affected 
by a number of outlying factors often present before the emer-
gence of the first depressive symptoms. Therefore, in addition to 
their lack of specificity to MDD, the diagnostic value of individual 
inflammatory biomarkers could be hindered by some inherent 
heterogeneity of depression. Although they may be useful as 
MDD biomarkers in a research environment, their low sensitiv-
ity and specificity (6) prevent them from being utilized in the 
majority of clinical settings.
In contrast to the relatively limiting findings of individual 
inflammatory analyte concentrations as biomarkers for depres-
sion, inflammatory markers have potential use as state markers 
by characterizing treatment response to antidepressants (94, 
95). Significantly, antidepressant effects are associated with a 
decrease in proinflammatory/anti-inflammatory protein ratios, 
especially in patients that respond to treatment when compared 
to non-responders or healthy controls (96). Specified inflam-
matory markers tend to correlate well with treatment efficacy 
in depressed patients. For instance, TNF-α levels have been 
reported as a marker of treatment response and psychopathologi-
cal improvement (94, 97). However, a recent meta-analysis (98) 
failed to detect pharmacological effects on serum levels of TNF-α, 
although they reported that IL-1β levels decreased after antide-
pressant treatment. Another analyte, high sensitivity C-reactive 
protein (hs-CRP), was found to be a highly specific baseline 
biomarker when evaluating patient response to Infliximab in 
treatment-resistant depression (TRD) (99). Similarly, CRP 
levels have been used to differentially evaluate treatment efficacy 
between escitalopram and nortriptyline (100). Considering 
the high incidence of treatment resistance in MDD-diagnosed 
patients, inflammatory markers capable of determining antide-
pressant treatment response will have a significant impact on 
depression management and allow practitioners the ability to 
modify treatment plans according to personalized histories and 
peripheral biomarker results. For further review, please read the 
following articles: Dantzer et al. (101), Leonard and Maes (102), 
Miller et al. (9, 75), Müller and Schwarz (103), Raison and Miller 
(104), and Young et al. (105).
Markers of Oxidative Stress
Oxidative stress has also been proposed to have an important 
role in depression pathology (102, 106–108). Consistent with 
preclinical studies that display increased antioxidant capacity 
with antidepressant therapy (109–111), human studies have 
demonstrated that increased oxidative activity is reversible by 
SSRI action in severely depressed, medication-naive patients 
(112) or melancholic patients (113), implying the involvement 
of oxidative processes in depressive disorders and monoamine 
metabolism. However, one study (114) found that treatment with 
antidepressants did not affect oxidative–antioxidative markers 
in MDD subjects while another found increased oxidative stress 
after treatment (115). An explanation for these inconsistent results 
may be the varying oxidative effects of different antidepressant 
formulations and duration of treatment that vary between stud-
ies. Whatever the case, the extensive literature associating oxida-
tive processes and depression suggests markers of oxidative stress 
may be able to identify depressed patients and quantify severity.
Several studies have found significantly increased oxidative 
stress markers [e.g., 8-hydroxy-deoxyguanosine (8-OHdG), F2 
isoprostane, peroxidase, malondialdehyde (MDA), and super-
oxide dismutase (SOD)] and decreased antioxidative capacity in 
MDD patients (112–118). Some studies have also demonstrated 
specific correlations of depressive subtypes or features with 
oxidative stress, yet results remain conflicting. Decreased GSH 
has also been found to correlate with severity of anhedonia in 
depressed patients (119), while plasma GSH-R and erythrocyte 
glutathione peroxidase (GPX) levels were elevated in MDD 
patients with melancholic features (113). A study determining the 
relationship between psychological responses and 8-OHdG levels 
found a positive correlation with depression–rejection scores of 
the POMS scale in females compared to a negative correlation 
in men, suggesting gender differences in depression-associated 
oxidative damage markers (120). Additionally, increased expres-
sion and distribution of allele frequencies of enzymatic proteins 
involved in the production of oxidative free radicals (e.g., induc-
ible nitric oxide synthase and myeloperoxidase) were character-
istic of patients with recurrent depression (121). Recently, Smaga 
and colleagues (122) completed a review of a number of clinical 
studies that demonstrated higher oxidant status in depressed 
patients including higher plasma peroxide levels, higher nitric 
oxide levels in serum, and higher xanthine oxidase levels. The 
authors also found that oxidative DNA damage and higher levels 
of lipid peroxidation markers were also prevalent in a number of 
depression studies.
In elderly populations, free radicals have been implicated in 
the pathophysiology of other neurodegenerative disorders along 
with MDD (123, 124). A study by our group has shown increased 
CSF F2-isoprostanes in geriatric patients diagnosed with MDD; 
further, an inverse relationship was found between amyloid-β 
42 and F2-isoprostane CSF levels, suggesting that increased 
oxidative stress pathology may be associated with increased brain 
amyloid burden (125). These findings are corroborated by other 
published findings that imply similar pathological mechanisms 
(e.g., increased levels of lipid peroxidation) between MDD and 
chronic, age-related diseases (126). Due to the complex neuro-
biological complications that are present in late-life depression, 
there is a need to identify specific markers in order to direct 
biology-based treatment.
Neurotrophins
Neurotrophins [i.e., nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF), neurotrophin (NT)-3, -4, and -5] 
are homodimeric proteins that interact with the tropomyosin 
receptor kinase (Trk) family of receptors through which they 
mediate the processes of neurogenesis and neural plasticity in 
both the peripheral and central nervous systems (127). Several 
connectomic studies have increasingly indicated the disruption 
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of integral whole-brain structural networks in MDD, suggesting 
the presence of abnormal neuronal synapse formation within 
certain populations of depressed patients (128, 129). In fact, there 
is evidence that disrupted neurogenesis may be a characteristic of 
MDD pathophysiology, especially of the hippocampus (130, 131). 
Due to the role of NTs in neuroplastiticty, their use as potential 
biomarkers has often been reviewed. Of these, the most researched 
is BDNF, with studies finding its downregulation in the limbic 
structures of chronic-stress exposed rats and reports of decreased 
peripheral levels in MDD patients (132–136). Significantly, 
a recent study (137) has shown serum BDNF may also have 
significant potential as a discriminatory diagnostic tool for first 
major depressive episode (MDE) patients, prompting the need 
for more expansive studies concerning its use in clinical settings. 
While there have been conflicting results concerning correlations 
of depression severity with BDNF levels (138), BDNF concentra-
tions have been reported to increase after antidepressant therapy 
with more prominent elevations in patients with higher baseline 
depression severity (139–145). Several studies have also reported 
elevated BDNF levels in responders to antidepressant treatment 
compared to non-responders that continued to demonstrate 
lower BDNF concentrations after pharmacologic management 
(146, 147). These findings suggest that BDNF may be utilized 
as a state marker to assess psychopharmacological therapy and 
prognosis of individual MDD patients (148), although the effect 
on BDNF levels may vary between different classes of antidepres-
sants (149). Ultimately, due to its intrinsic function in influencing 
the development and maintenance of a patient’s cognitive abilities, 
BDNF could have potential for evaluating other therapy effects 
involving learning, memory, and executive functions (134, 150).
Alternatively, de Azevedo Cardoso and colleagues (151) have 
suggested that BDNF may also have trait-like properties. For 
example, differences between male and female BDNF levels have 
been associated with contrasting antidepressant effects between 
the two genders (145). Additionally, there is evidence that BDNF 
levels are more negatively affected in patients with chronic 
depression who have experienced more adverse life events (152). 
Supporting this theory, several groups have illustrated how BDNF 
genotypic variations were associated with risk for depression 
(151, 153–157). BDNF DNA methylation patterns have also been 
associated with depression severity, and the presence of suicidal 
ideation in MDD subjects (158–160). Consequently, the potential 
for BDNF to be a trait and state-like marker makes it one of the 
more versatile biomarker candidates being researched today.
In contrast, fewer studies have focused on other NTs, with the 
notable exception of NGF, which has been found to be increased 
during circumstances that cause anxiety or anticipation of anxi-
ety (161). Regarding NGF’s relationship to depressive symptoms, 
reports of NGF concentrations have yielded conflicting results 
(151, 162, 163). Additionally, due to its association with other 
affective disorders such as bipolar disorder (BPD) (164); it is 
unlikely to be specific to MDD. These limitations, however, 
should not preclude it from further research.
Markers in Genetics and Genomics for MDD
Past studies have suggested that there is a complex genetic 
component to the development of MDD, with evidence that 
heritability is a key factor in a significant number of depression 
cases (165–167). Additionally, several studies have revealed vari-
ous polymorphisms and overexpression of certain genes in patients 
presenting with depressive symptoms (168–170). One example 
is a blood-based study that found increased serotonin type 1A 
receptor (5-HT1A) expression within platelets of MDD patients 
compared to controls (171). The authors also reported decreased 
levels of serotonin (5-HT), platelet poor plasma (PPP) 5-HT, and 
a decrease of the 5-HT metabolite, 5-hydroxyindoleacetic acid 
(5-HIAA), suggesting that increased 5-HT1A expression inversely 
correlated with 5-HT activity via a negative feedback mechanism. 
Often, such genetic variants imply pathological mechanisms 
associated with the dysfunction of different biological systems 
implicated in depression. Another example is HPA axis hyperac-
tivity, which is believed to influence the pathogenesis of MDD due 
to findings of GR and mineralocorticoid (MR) receptor dysfunc-
tion in depressed patients (24). For instance, a longitudinal study 
focusing on neuropsychiatric disorders in an elderly community 
found that several single-nucleotide polymorphisms (SNPs) of 
angiotensin-converting enzyme (ACE) were significantly associ-
ated with the risk of late-life depression (172). Additionally, they 
reported that two SNPs (rs4291 and rs4295) were associated with 
the risk of incident depression over the study’s 10-year follow-up. 
More recent studies have determined that polymorphisms of the 
FKBP5 gene (a gene that plays a role in immune regulation) also 
modulate GRs, and have been associated with the development 
of depression (20–23). A meta-analysis of HPA axis dysfunction 
associated with GR abnormalities found that glucocorticoid-
induced leucine zipper (GILZ), a product of GR-initiated gene 
transcription, has been suggested to be associated with biological 
pathways relevant to depression (173). Though few studies have 
focused on GILZ concerning depressive disorders, there is 
clinical evidence that a reduction in its expression is associated 
with reduced hippocampal volumes found in MDD-diagnosed 
subjects (174).
More comprehensive data concerning the heritability of 
depressive disorders will likely come from the increasingly com-
plex genome-wide research being conducted today. For example, 
the GeneQol Consortium (175) gathered data from a substantial 
number of studies that undoubtedly demonstrate the involvement 
of genetic variables in quality of life (QOL) domains (e.g., fatigue, 
pain, general functioning, social functioning, general health). Of 
the biomarker candidates they reviewed, candidate genes and 
molecular markers that had the most evidence of association 
with QOL domains were genes for inflammatory cytokines (e.g., 
IL-1β, IL-6, IL-8, and TNF-α). Additionally, inflammatory mark-
ers (e.g., CRP) and anti-inflammatory markers (e.g., IL-1RN, 
IL-1RA, and IL-10) were also associated with a smaller number 
of QOL domains. Other QOL-associated markers include genes 
for dopaminergic and serotonergic synapses [MAOA, 5-HTT 
(SLC6A4), TPH1], the glutathione metabolic pathway (DPYD), 
and pain receptor pathways (OPRM1). However, the specific-
ity and accuracy of these markers for MDD may be limited by 
significant genetic heritability among psychiatric disorders 
(176), and the fact that current MDD genomic data is limited 
by heterogeneity and insufficient power (177). Yet, these findings 
still underlie the potential of genetic irregularities to play a role in 
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more accurately characterizing and diagnosing depressive disor-
ders. Currently, better powered studies are required to determine 
the etiologic and genetic variables involved in MDD pathology, 
especially when conducting genome-wide research.
MicroRNAs (miRNAs) are a popular genetic marker in 
researching MDD biomarkers due to their role as small RNA 
regulators involved in neural stem cell proliferation, neurogenesis, 
and neural plasticity (178). In addition, several miRNA alterations 
were associated with an increase in risk for major depression and 
negatively regulate the expression of either serotonin receptors 
(SERT) or 5-HT1B receptors (179). Significantly, one study (180) 
has indicated that miRNA profiles are capable of separating 
MDE patients from controls while a second study (181) found 
30 miRNAs to be differentially expressed in MDD patients after 
escitalopram treatment. These findings are further corroborated 
by results from a study demonstrating gene variations in Drosha 
RNase and Digeorge syndrome critical region 8 (DGCR8), a 
known cofactor in miRNA processing, and AGO1, a component 
protein involved in the production of mature miRNAs, as being 
capable of significantly differentiating MDD patients and healthy 
controls in relation to genotype and allele frequencies (182). 
Another study demonstrated that dysregulation of circadian 
rhythms in MDD patients was associated with the rs76481776 
polymorphism of miR-182, suggesting that symptoms of MDD 
may be inherently linked to genetic variations that affect miRNA 
function (183). These distinctive miRNA profiles in depressive 
disorders predispose them to becoming a promising source of 
biomarkers for MDD research and diagnostics. With more studies 
confirming their involvement in depression and with advances in 
miRNA expression measurement techniques (184), miRNA data 
may prove to be useful additions to MDD biomarker panels.
Several studies have demonstrated an association between 
telomere length and depressive disorders. Szebeni and colleagues’ 
recent post-mortem study, previously described, found decreased 
expression of telomerase reverse transcriptase (TERT), an 
enzyme whose function is to prevent telomere shortening (TS), in 
oligodendrocytes derived from different parts of the brain (185). 
Another study found over expression of certain genes involved 
in propagating TS in the leukocytes of female MDD subjects 
(186). Specifically, these genes have been associated directly or 
indirectly with telomere dysfunction (STMN1, P16ink4a), oxidative 
stress (OGG1), and aging (OGG1) while others (FOS, DUSP1) 
were linked to the stress-related p38MAPK pathway, although 
they are not specific to depression and may be found in normal 
aging or anxiety disorders (186). In fact, at least one large-scale 
study has shown an association between symptoms of anxiety and 
TS in comparison to depression-associated telomere dysfunction 
over a 2-year period of time (187). Considering that telomere 
length is a biomarker of cellular aging, it is not surprising that it 
is more commonly associated with chronic periods of life-long 
depression rather than acute episodes (188).
Yet, shorter telomere lengths have also been observed in 
children of lower socioeconomic status with coexisting dopamin-
ergic/serotonergic genetic sensitivity to harsher social environ-
ments (189). This study suggests that significant stress at an early 
age may be associated with genetic and biological changes that 
predispose children to depressive disorders. Therefore, TS may 
not be exclusively valuable as a biomarker in older populations, 
but may also be useful in identifying children who are more prone 
to TS as a result of immature protective mechanisms against 
inflammatory, oxidative, and HPA-axis effects on cellular genetic 
coding. Furthermore, a recent study reported a negative correla-
tion between telomere length and cortisol reactivity in female 
adolescent subjects with familial risk for depression (190). This 
study implies how inherent HPA axis dysregulation, consistent 
with biological changes in depression pathology, is associated 
with TS that typifies the accelerated cellular aging in younger 
cohorts (190). Accordingly, such studies indicate TS could find 
more use as a predictive or screening marker in younger and 
geriatric populations, respectively, than a specific biomarker 
for MDD. However, a recent large-scale study found increased 
mitochondrial DNA and shortened telomere length in subjects 
with major depression status, but did not find either variable to 
correlate with increased risk of developing major depression, 
suggesting characteristics of a state biomarker (191). Further 
research will be required to elucidate the basis for these contrast-
ing findings.
Lastly, significant consideration should be given to the diffi-
culty of directly associating genetic phenotypes with psychiatric 
disorders. In response to this challenge, Gottesman and Gould 
(192) proposed criteria for developing endophenotypes, interme-
diary constructs that would act as tractable traits that could more 
effectively characterize the heritability of psychiatric disorders. 
Hasler et al. (193), and more recently, Goldstein and Klein (194) 
have published detailed reviews about both psychopathological 
(e.g., neuroticism, anhedonia, depressed mood, increased stress 
sensitivity), and biological (e.g., morning cortisol, tryptophan 
depletion, DEX/CRH, CRH dysfunction, hippocampal volume, 
and reduced 5HT1A receptor expression) endophenotypes for 
depression. However, there continues to be a relative lack of 
evidence for current putative endophenotypes, specifically due 
to a deficiency of family and twin studies (194). It is therefore 
possible that future endophenotype studies and analysis may 
contribute to the growing literature characterizing MDD as well 
as further the development and understanding of MDD etiology 
and pathophysiology that remain the most heterogeneous com-
ponents of the disorder.
epigenetics
Epigenetic mechanisms have been used to explain how early life 
exposures to toxic or stressful stimuli may contribute to the pre-
disposition or development of mental illness (195). For depressive 
disorders, histone modification at the amino (N)-terminal tails 
and DNA methylation has been the most studied in determining 
how epigenetic factors affect the progression, severity, symp-
tomatology, and treatment response of depression (196, 197). 
Significantly, these epigenetic modifications may affect expres-
sion of certain receptors (e.g., GR receptors in the hippocampus), 
which leads to either an increased or decreased risk for depression 
in the future (196). This is supported by animal studies that show 
antidepressant-like effects of histone deacetylase inhibitors (195, 
196, 198–200), which are thought to induce histone acetylation 
in certain regions of the brain. Overexpression of DNA methyl-
transferases also leads to an increase in DNA methylation and 
7Young et al. Overview of MDD Biomarker Candidates
Frontiers in Psychiatry | www.frontiersin.org April 2016 | Volume 7 | Article 72
has been associated with abnormal dendritic spine plasticity and 
alterations in behavioral responses. Supporting this, one group 
found site-specific hypermethylation of TrkB-T1 to be increased 
in suicide completers (201), suggesting a pattern of methylation 
abnormalities in subjects with depressive phenotypes. Recently, 
epigenome-wide association studies have demonstrated several 
genes with methylation associations in depressed subjects 
compared to controls. As these studies are mostly array-based, 
they have had the advantage of investigating the entire genome, 
but replication studies are currently lacking (202). One recent 
genome-wide study (203) was able to separate medication naive 
MDD subjects from controls by observing differences at 363 
CpG sites that differed from the pattern they observed in their 
schizophrenia patients (204) indicating disease-specific patterns. 
Furthermore, several candidate gene studies involving DNA 
methylation have been investigated and include genes that have 
been previously implicated in depression. Among these genes, 
SLC6A4, BDNF, and NR3C1 have been the most studied, with 
BDNF methylation having the most consistent data concerning 
associations between DNA methylation and depressive symp-
toms/antidepressant response (202). This study demonstrated a 
significant association between depression and methylation levels 
of BDNF at specific CpG sites. Notably, the authors have shown 
that such robust biomarkers may come from easily obtainable 
specimens such as buccal samples. Although epigenetic research 
is still in its infancy, these epigenetic mechanisms and resulting 
patterns in chromatin remodeling are becoming established as a 
basis by which chronic social defeat, early life stress, variability 
of maternal care, and antidepressant therapy may influence the 
progression or resolution of depressive symptoms (197, 202, 
205, 206). Further studies and elaboration on these mechanisms 
will likely lead to significant advances in the development of an 
epigenetic model from which MDD biomarkers may be retrieved. 
Please see Nestler et al. (195), Tsankova et al. (197), and Januar 
et al. (202) for further review.
PROTeOMiCS, MeTABOLOMiCS, AND 
THe UTiLiTY OF MULTiPLeX ASSAYS
Proteomic and Metabolomics Research
There have been recent technological advances that have allowed 
more in-depth characterization of medical disorders on both the 
analytical and clinical level. Mass spectrometry (MS) proteomics 
has allowed researchers to quantify expression levels of proteins 
for detecting changes after translation or protein interactions 
(207). High performance liquid chromatography (HPLC) has 
been used to separate and assess proteomes/metabolites in both 
schizophrenia (208) and BPD (209). With depression, Martins-
de-Souza’s group was able to observe differing levels of various 
proteins involved in metabolic pathways and molecule transport 
between MDD subjects and control subjects (P <  0.05) (210). 
Interestingly, they found that those with MDD who developed 
psychosis had differentially expressed proteins that were different 
from MDD subjects who did not develop psychosis. Thus, their 
report suggests that proteomes may aid in the characterization 
of MDD subtypes and the varied symptomology of psychiatric 
patients. There has also been an increase in use of high-resolution 
nuclear magnetic resonance (NMR) spectroscopy to evaluate 
biofluids to not only document baseline levels of metabolites but 
also produce complete time-lines of metabolite variability that 
may result from drug administration or medical disorders (211). 
Consequently, a number of recent studies have taken advantage of 
these more complex analytical tools to search for possible MDD 
biomarkers in different biological systems.
Using gas chromatography/MS (GC/MS) coupled with 
multivariate statistical analysis, Ding and colleagues were able to 
produce distinct blood-based metabolic profiles that were able to 
separate MDD patients from healthy controls (212). Critically, 
their study found significant separation between a subgroup 
of MDD patients with “early life stress” (ELS) versus those that 
did not have ELS, indicating possible use for characterizing 
depressive subtypes. Their investigation further supports the 
theory of separate pathophysiologic mechanisms that cause 
differing metabolite concentrations between MDD subtypes. 
This is a significant finding given that ELS has been considered a 
preventable risk factor for a number of pathological psychiatric 
disorders (213). Similarly, Zheng and colleagues (214) used a GS/
MS-based urinary metabolite signature to demonstrate signifi-
cant separation of MDD from controls in both training samples 
and an independent test cohort that included medicated MDD 
subjects. Another group used HPLC to evaluate plasma levels of 
glutamic acid, aspartic acid, glycine, gamma-aminobutyric acid 
(GABA), and nitric oxide (NO) of medication-naive melancholic 
MDD patients, and differentiate them from matched controls 
(215). The resulting data indicated that plasma GABA levels 
were associated with anhedonia and suicidal ideation in affected 
MDD subjects. The authors observed that the studied analytes 
could be used as trait-like biomarkers since metabolite plasma 
concentrations continued to be abnormal even after 2  months 
of fluoxetine treatment despite having no significant correlation 
with Hamilton Depression Rating Scale (HAM-D) scores or 
severity of depression. The results of this study may indicate how 
dysregulation of the metabolism of monamine neurotransmitters 
may vary and predict the course of depression in certain individu-
als. Ditzen et al. (216) used 2D polyacrylamide gel electrophoresis 
and time-of-flight MS peptide profiling to determine differences 
in CSF proteomes between depressed patients and controls 
finding 11 significantly differentially expressed proteins and 16 
phosphorylated proteins that separated the two groups. These 
proteins have been implicated in CNS diseases, nervous system 
development, and cell death. Additionally, Stelzhammer and col-
leagues (70) have demonstrated a number of proteomic changes 
in first onset, drug-naive MDD patients including markers of 
inflammation (ferritin, EN-RAGE, ceruloplasmin, IL-16, sero-
transferrin, tenascine-C), oxidative stress (cortisol), RAS markers 
(ACE), and changes in growth factors (BDNF and GH). Lastly, 
Wang and colleagues (217) have also reported consistently high 
sensitivity, specificity, and accuracy in discriminating between 
MDD subjects and healthy controls by using matrix-assisted laser 
desorption ionization time-of-flight MS to determine peptide 
profiles in first episode, drug-naive MDD. The potential for a 
laboratory-based analysis to aid in MDD patient identification 
validates future research using these developing technologies 
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along with further evaluating any candidate biomarkers found to 
be capable of discriminating affective disorders.
emerging Multiplex-Based Biomarkers
Though there have been a number of studies analyzing the various 
neurobiological features persistently found in depressed patients, 
no specific marker from a single biological system has been 
capable of significantly improving upon the current diagnostic 
criteria set for MDD patients. As several of the aforementioned 
biomarkers seem necessary but not individually sufficient, 
multiplex assays are currently the most promising to contribute 
consistent results to aid in further standardizing MDD diagnosis 
and research. As past studies have demonstrated, depression 
pathology is influenced by disruption from multiple systems 
including the HPA axis, oxidative pathways, inflammatory 
processes, and neurotrophic homeostasis. Collectively measur-
ing the putative analytes of each system will likely increase the 
power of any diagnostic panel developed for MDD. This concept 
is supported by studies that used multiple analytes of different 
origins and considered to be potential biological markers of 
depressive disorders to increase specificity and sensitivity in 
diagnosing MDD. One study worth noting achieved high sensi-
tivity (above 90%) and specificity (above 80%) in distinguishing 
MDD patients from healthy controls (218). The authors used nine 
biomarkers from different biological sources such as inflamma-
tory and oxidative indices (α1 antitrypsin, apoplipoprotein CIII, 
myeloperoxidase, soluble TNFα receptor type II); the HPA axis 
(epidermal GF, cortisol); neurogenesis (BDNF); and metabolism 
(prolactin, resistin) to develop an algorithm that produces a score 
that could potentially be used for an objective diagnosis of MDD. 
In addition to achieving high sensitivity and specificity in their 
pilot study, Papakostas et al. also produced a similar performance 
in their replication study. This group further refined their model 
algorithm by factoring in gender, BMI, and normalized cortisol 
levels (219). Another group used CSF concentrations of multiple 
analytes including inflammatory biomarkers (IL-6), serotonin 
metabolites (5-hydroxyindoleacetic acid), dopamine metabolites 
(homovanillic acid), and HPA axis biomarkers (hypocretin) to 
detect severe suicidal behavior and increased risk of complet-
ing suicidal attempts in MDD patients (220). Likewise, CSF 
protein biosignatures were found to be capable of discriminating 
depressed, bipolar, and schizophrenic patients from healthy 
controls (221). These markers included proteins involved in 
neurogenesis (e.g., neuronal growth regulator 1, neural prolif-
eration differentiation and control protein); neurotransmission 
(seizure-related 6 homolog protein); and oxidative damage (GPX 
3). However, Maccarrone and colleagues have indicated difficul-
ties differentiating between individual psychiatric disorders and 
controls, as only a few proteins of their CSF biosignatures were 
found competent enough to distinguish between disease groups. 
They have reported high accuracy rates of distinguishing bipolar, 
depressed, and schizophrenic patients (i.e., 83.3% for MDD). 
Other multiplex studies that have been discussed in previous 
sections have also shown significant inflammatory/oxidative 
features (70) and epigenetic variations (203) in MDD subjects. 
Due to their inherent sophistication and more comprehensive 
analysis relative to individual markers, these multiplex assays 
have the potential to reduce inconsistent data that develop due to 
differences in study populations and methods seen in past, single 
biomarker studies (219). However, it is currently imperative to 
conduct future studies that focus on replicating and confirming 
such findings that yield increased MDD diagnostic accuracy 
using these methods.
LiMiTATiONS OF CURReNT ReSeARCH
The main variables that are consistently problematic in the 
development of a reliably viable MDD biomarker involves the 
heterogeneity of depressive disorder pathophysiology, etiology, 
and study designs, which in turn may contribute to conflicting 
data. As a result, variations between studies reviewed here limit 
the precision and generalizability of the findings. Additionally, 
although with notable exceptions mentioned [e.g., the ADNI 
study and Vreeburg et al. study (29)], most studies we reviewed 
collected data from small samples sizes often consisting of fewer 
than 100 subjects. Another difficulty is how to consistently associ-
ate biomarkers with DSM criteria for MDD (e.g., low mood, poor 
concentration, suicidal ideation), which are not always necessary 
in diagnosing depression and could be present in other psychiatric 
disorders including schizophrenia. Consequently, any biomarkers 
that are heavily associated with non-specific clinical symptoms 
of depression may produce a high rate of false positives. This is 
significant as the majority of studies focus on exploring biologi-
cal differences between depressive disorders and control groups, 
but do not extensively evaluate putative biomarkers’ diagnostic 
specificity against other psychiatric disorders. Although current 
research has an increasing neuroscience focus advocated by the 
National Institute of Mental Health through the novel Research 
Domain Criteria (RDoC) project (222), we are likely decades 
away from discovering the basic underpinnings of neurobiologi-
cal changes present in psychiatric disorders and how they relate 
to behavioral shifts; discoveries that are necessary to determine 
the adequacy of developing biomarkers (223). Consequently, the 
only standards available to compare the validity and specificity of 
diagnostic biomarkers are syndromic and descriptive categories 
developed by expert consensus (224). Although the most recent 
research on MDD biomarkers has suggested the possibility of 
finding more objective forms of diagnostics compared to the 
aforementioned diagnostic criteria in clinical use today, it is still 
unclear how these discrete markers would relate to the diverse 
clinical presentations and differing populations that continuously 
confound research on MDD.
CONCLUSiON
Multiple biological pathways are robust sources of tissue-based 
MDD biomarkers with trait and state characteristics. However, 
individual biomarkers currently impart limited clinical utility. 
In the future, multiplex assays comprised of putative depression 
biomarkers may improve upon the clinical evaluation of MDD, 
assess treatment efficacy, and serve to standardize discharge 
criteria. However, independent replication studies with large 
sample sizes are needed to fully substantiate the validity of such 
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panels. Furthermore, the use of these markers are limited by high 
costs and confounding factors associated with each component 
of prospective diagnostic constituents (225). If these markers 
become reproducible and translate into readily available diagnos-
tic tools with ease of access, low cost, rapid formulation, and high 
sensitivity/specificity, the implications for clinical use would be 
tremendous. After decades of investigations and several promis-
ing markers falling into obscurity, it is difficult to say whether 
we are getting closer or farther away from one of the holy grails 
of diagnostic biomarkers for depression. Suffice it to say, every 
study that contributes to the development of such biomarkers will 
assuredly be needed if such a goal is to be achieved. As the RDoC 
project and current technology evolve to lessen the limitations of 
past studies, future large-scale MDD biomarker studies will be 
necessary to yield advances that will hopefully have utility in the 
clinical setting.
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